Illicit, unapproved copies of the experimental weight-loss drug retatrutide are being sold globally, raising significant safety concerns among medical professionals.
Key facts
- •Retatrutide has not been approved for human use by any regulatory body.
- •Eli Lilly has reported more than 14,000 websites and social media posts for illegally marketing the drug.
- •Counterfeit versions are being sold in gyms, nail salons, and on social media platforms.
- •Users of fake retatrutide have reported side effects including kidney failure, brain fog, and loss of libido.
- •The UK's MHRA has conducted raids and seizures of products claiming to contain the drug over the past year.
The experimental weight-loss drug retatrutide, currently under development by Eli Lilly, has not yet received regulatory approval for human use. Despite this, counterfeit versions of the drug are flooding the black market in the UK and globally. Experts warn that these illicit products are being sold in gyms, salons, and on social media, posing severe health risks to users who are consuming substances with unknown ingredients and purity levels.
By the numbers
Safety Risks and Medical Concerns
Medical experts report that patients are presenting at hospitals with symptoms including nausea, vomiting, diarrhea, and kidney failure after using counterfeit retatrutide. Endocrinologist Prof. Donal O'Shea noted that some users are being injected by personal trainers without knowing the contents or proper dosage of the substance. Because the drug is still in Phase III clinical trials, its safety and efficacy remain unproven, and only about 50% of drugs at this stage of testing eventually receive FDA approval.
Regulatory and Corporate Response
Eli Lilly has warned that illicit retatrutide products may contain harmful contaminants or incorrect active ingredients. The company is actively working with law enforcement and regulatory bodies, reporting over 14,000 websites and advertisements for illegal marketing. In the UK, the Medicines and Healthcare Products Regulatory Agency (MHRA) has conducted raids and seizures of products claiming to contain the drug to disrupt illegal distribution networks.
Development Timeline
Retatrutide is designed to act on three hormone receptors, including the novel glucagon receptor, which distinguishes it from existing weight-loss medications. Eli Lilly expects to submit an application for US FDA approval early next year. If approved, the drug would not be legally available in the US until late 2027 at the earliest, with potential UK market availability following in 2028.
Timeline
- Early next yearEli Lilly plans to submit its application for US FDA approval.
- End of 2027Earliest possible date for legal availability in the US.
- 2028Potential earliest date for market availability in the UK.
Advertisement
This article was independently rewritten by ManyPress editorial AI from reporting originally published by BBC Health.
